Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REM 0046127

Next Previous
X
Search
Drug Profile

REM 0046127

Alternative Names: REM-0046127

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator reMYND
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action ORAI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 04 Jun 2024 reMYND terminates phase-II clinical trials in Alzheimer's disease in Netherlands (PO) due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause (NCT05478031)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers, In adults) in Austria (PO)
  • 07 Jun 2022 Phase-II clinical trials in Alzheimer's disease in Netherlands (PO) (NCT05478031)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top